亚洲精品自拍视频 I 精品人妻码一区二区三区 I 国产成人黄色在线观看 I 91视频国产一区 I 欧美高清freexxxx性 I 91久久天天躁狠狠躁夜夜 I 精品国偷自产在线视频九色 I 久久免费视频6 I 亚洲精品有码在线观看 I 国产在线亚州精品内射 I 亚洲综合欧美制服丝袜 I 日本大黄色片 I 成人射区 I 九九精品免费 I 秋霞国产午夜伦午夜福利片 I 亚洲精品天堂网 I 日韩在线播放av I 貂蝉艳史在线观看 I 亚洲日本韩国精品 I 午夜福利影院私人爽爽 I 国产免费这里只有精品 I 国产亚洲精品久久久久久动漫 I 欧美理论视频 I 天天干天天干 I 国产毛片久久久 I 一区二区三区在线播放 I 亚洲色一色噜一噜噜噜 I 亚洲黄色免费在线看 I 日韩精品一卡2卡三卡4卡 I 91.com在线

SHANGHAI – February 23 2022  Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing in its Phase 1b (MAD) clinical trial of topical TDM-105795 solution in patients with Androgenetic Alopecia (AGA). This second clinical trial in the program is a 28-day multiple dose escalation study entitled, “A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects with Androgenetic Alopecia”. Study objectives are to evaluate the safety and pharmacokinetics of topical TDM-105795 following repeated doses. Two U.S. clinical sites are currently participating in this study.

Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We also expect the current study results to guide choice of formulation strength(s) appropriate for a subsequent proof-of-concept (PoC) Phase 2 Androgenetic Alopecia study. The Company anticipates the robust induction of hair growth demonstrated by TDM-105795 in preclinical testing should be observable within several months of initiating treatment.”

“We look to the TDM-105795 AGA program as the first clinical anchor among our pipeline products for treatment of various dermatologic diseases,” said Zengquan Wang, Chief Executive Officer at Technoderma Medicines. “We are working tobring a second pipeline product (Atopic Dermatitis) into clinical testing soon in mid-year.”